News | September 02, 2021
Granules India receive DRDO licence to manufacture and market 2-DG
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
_256_384.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
PPH is associated with almost 20 per cent of maternal mortality in India
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Self-collection devices designed for ease of use and safety
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Subscribe To Our Newsletter & Stay Updated
